This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment of colon cancer

Authoring team

Treatment options of colonic carcinoma consists of

  • surgical resection of the lesion.
    • colectomy with en bloc removal of the regional lymph nodes in resectable non metastatic colon cancer (1)
    • resection of metastatic disease and colectomy (same time or separately) in metastatic tumours which are considered resectable (2)
  • chaemotherapy
    • adjuvant chaemotherapy after surgery for high-risk stage II and stage III colon cancer (2)
    • preoperative chaemotherapy for resectable metastatic disease (1)
    • palliative chemotherapy in patients with locally advanced or metastatic disease has been shown to reduce death and progression at 12 months (1). The findings translate into a 16% absolute difference in survival and a 25% increase in progression free survival (increases in 3.7 months in median survival and 6 months in median progression free survival) in patients treated with palliative chemotherapy e.g. 5-fluorouracil alone or in combination with other chemotherapeutic agents.
  • biological agents (2,3)

The response to radiotherapy is limited by the difficulty of directing the radiation beam at the tumour without damaging surrounding structures, e.g. the bladder.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.